This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Dothiepin hydrochloride

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Dosulepin hydrochloride (former British Approved Name (BAN) dothiepin hydrochloride) is indicated in depressive illness; particularly where sedation is required.

Contra indications include recent myocardial infarct, heart block, mania; porphyria.

Side effects include a dry mouth, sedation, blurred vision, constipation, nausea, difficulty with micturition. Cardiovascular side effects include arrhythmias, postural hypotension, syncope. Other side effects include sweating, tremor, rashes, behavioural disturbances - especially in children, interference with sexual function, hypomania, and confusion - especially in the elderly.

Uncommon side effects include black tongue, paralytic ileus, agranulocytosis, leucopenia, eosinophilia, purpura, thrombocytopenia, and jaundice.

The summary of product characteristics should be consulted before prescribing this drug.

Notes:

  • dosulepin, phenelzine, combined antidepressants, and lithium augmentation of antidepressants should only be routinely initiated by specialist mental health professionals, including General Practitioners with a Special Interest in Mental Health (1)

Reference:

  1. NICE (December 2004).Depression Management of depression in primary and secondary care

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.